Parliament Workbench
Data: Motions & questions to 19 Nov 2026

Written Question · S1W-15920 · Session 1

Further to the answer to question S1W-12217 by Susan Deacon on 11 May 2001, what its timetable is for achieving a significant reduction in …

Answered Asked by Mary Scanlon Con Lodged 22 May 2001

The question

To ask the Scottish Executive, further to the answer to question S1W-12217 by Susan Deacon on 11 May 2001, what its timetable is for achieving a significant reduction in variations in prescribing practice across Scotland.

The answer

Answered by Susan Deacon on 28 Jun 2001 · 37 days after it was lodged, 23 days after it was due

Following a commitment in Our National Health, the Chief Medical Officer has asked Professor David Lawson to lead work with the Health Technology Board for Scotland and with local area drug and therapeutic committees on removing inequities in prescribing practice across Scotland. As a result of this, a seminar was held on 16 May at which the concept of a Scotland-wide consortium of Area Drug and Therapeutic Committees
- a Scottish Medicines Consortium
- was launched. This would provide a single source of Scottish advice to clinicians as close to the time of marketing of a new drug as possible. The Health Technology Board for Scotland has agreed to provide administrative and methodological support to the consortium. Discussions are ongoing with local area drug and therapeutic committees and health boards across Scotland and it is hoped that the consortium could begin operating in the autumn.

In the Official Report

No contribution in the Official Report cites S1W-15920 by reference.